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New 1-arylaminoimidazo[1,5-a]indol-3-ones were synthesized as cyclized derivatives of leucettine L41, a low 
molecular weight inhibitor of the DYRKs/CLKs protein kinases with potential applications in Alzheimer's 
disease and Down syndrome. In this first approach, access to the desired 1-aminoimidazo[1,5-a]indol-3-ones 
involved 5 steps and was explored with a series of various primary amines and polar secondary amines in order to 
introduce molecular diversity on N-1 position. The 5 step synthesis of the 1-arylaminoimidazo[1,5-a]indol-3-ones 
was achieved and the limiting step of this process was the final cyclization via a sulphur/nitrogen displacement 
from methylsulfanyl thiourea intermediates. Good results were obtained for isothioureas derived from primary 
amines. The 1-arylaminoimidazo[1,5-a]indol-3-ones were evaluated on a panel of five protein kinases 
(DYRK1A, CK1, CDK5/p25, GSK3 and CLK1). 
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INTRODUCTION 
 
Leucettamine B, a natural marine alkaloid comprising a 
2-aminoimidazoline-4-one scaffold, was isolated in 1993 from the 
sponge Leucetta microraphis Haeckel (Calcarea) of the Argulpelu 
Reef in Palau (Chan et al., 1993). Several total synthesis of 
Leucettamine B have been reported (Molina et al., 1994, Roué et 
al., 1999, Chérouvrier et al., 2001 and 2002, Debdab et al., 2009). 
Other marine natural products containing the 2-aminoimidazoline-
4-one core, such as polyandrocarpamine A (Cimino et al., 1982), 
hymenialdisine (Meijer et al., 2000, Xu et al., 1997, and             
Papeo et al., 2005) and zorrimidazolone (Aiello et al., 2011), are 
subject to intensive research by organic chemists, biochemists and 
biologists.  
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Among these molecules, (Z) hymenialdisine was identified as 
nanomolar inhibitor of various protein kinases (glycogen synthase 
kinase 3β (GSK3β, casein kinase 1 (CK1) and different cyclin-
dependent kinases (CDKs) (Wan et al., 2004).  
Protein kinases  catalyze phosphorylation on serine, threonine and 
tyrosine residues and regulate protein functions, stability and 
localization. They constitute very attractive therapeutic targets           
for the pharmaceutical industry in the search for new clinical  
drugs. 
Recently our group reported the patented synthesis of 
leucettamine B derivatives (Bazureau et al., 2009), collectively 
named leucettines, as low molecular weight inhibitors (Debdab et 
al., 2011 and Tahtouh et al., 2012) of DYRKs (dual specificity, 
tyrosine phosphorylation regulated kinases) (Aranda et al., 2011) 
and CLKs (cdc2-like kinases) (Hagiwara et al., 2005), two           
families of kinase involved in alternative pre-mRNA splicing and 
Alzheimer's disease/Down syndrome.  
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A detailed structure/activity relationship (SAR) study led 
to the selection of leucettine L41 (Figure 1) as a potent inhibitor of 
DYRKs and CLKs. To understand the kinase/inhibitor          
selectivities and to generate models for structure-based 
optimization, leucettine L41, was co-crystallized with DYRK1A 
and found to bind in the ATP pocket of this kinase by two               
direct polar interactions and hydrogen bonds (Debdab et al., 2011). 
Considering these biological results, particularly the hydrogen 
bonding network in the co-crystal structure, it was of interest to 
explore the building of 1-phenylamino imidazo[1,5-a]indol-3-one 
(Figure 1) which can be considered as an analog of leucettine L41 
obtained by the ring closure of N-C atoms between the N-1 
position of the 2-aminoimidazoline-4-one platform and the C-6 
position of the 1,3-benzodioxol-5-ylidene moiety. Here, we 
describe the synthesis of new 2-phenylamino imidazo[1,5-a]indol-
3-ones without substituents on the indolone moiety and evaluate 
their effects on five purified protein kinases. 
 
Fig.  1: Leucettamine B, Leucettine L41 and cyclized derivatives. 
 
MATERIALS AND METHOD 
 
Materials and instruments 
All reagents and solvents were purchased from Acros, 
Aldrich Chimie, and Fluka France and were used without further 
purification. Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were determined on a Kofler melting 
point apparatus and were uncorrected. 
1
H NMR spectra were 
recorded on BRUKER AC 300 P (300 MHz) spectrometer, 
13
C 
NMR spectra on BRUKER AC 300 P (75 MHz) spectrometer. 
Chemical shifts are expressed in parts per million downfield from 
tetramethylsilane as an internal standard. Data are given in the 
following order: d value, multiplicity (s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; br, broad), number of protons, 
coupling constants J is given in Hertz. The mass spectra (HRMS) 
were taken respectively on a MS/MS ZABSpec Tof Micromass 
(EBE TOF geometry) at an ionizing potential of 8 eV and on a 
VARIAN MAT 311 at an ionizing potential of 70 eV in the 
"Centre Régional de Mesures Physiques de l’Ouest" (CRMPO, 
Rennes). Elemental analyses were performed on a Carlo Erba 1106 
apparatus. 
 
Methods 
Standard procedure for the synthesis of N-carbamothioyl-1H-
indole-2-carboxamide 6(a-f) and N-carbothioyl-1H-indole-2-
carboxamide 6(f,g). 
In a 50 ml two-necked round-bottomed flask provided 
with a magnetic stirrer and condenser, a suspension of commercial 
indole-2-carboxylic acid 1 (1 g, 6.2 mmol) was vigorously stirred 
at room temperature in 25 ml of benzene. To this mixture was 
added dropwise phosphorous trichloride [0.85 g, 0.54 ml, 6.2 
mmol for compounds 6(a-e) or 1.7 g, 1.08 ml, 12.4 mmol for 
compounds 6(f,g)] during 30 min. at 25°C under a stream of Ar. 
The reaction mixture was heated in oil bath at 80°C during 1 hr. 
After cooling down to room temperature, the reaction mixture was 
filtered on a Buchner funnel (porosity N°4) and the resulting 
filtrate was concentrated until a final volume of 5 ml in a rotary 
evaporator under reduced pressure. This concentrated solution was 
poured in a 50 ml round bottomed flask provided with a magnetic 
stirrer and condenser. To this solution were added successively 30 
ml of acetone p.a. and potassium thiocyanate (603 mg, 6.2 mmol). 
This suspension was stirred at 25°C during 1 hr and primary amine 
4 (6.2 mmol) or morpholine 5a or 4-methylpiperazine 5b (6.2 
mmol) was added in one portion. The reaction mixture was stirred 
vigorously at 25°C during 1 hr, then the solvent was removed in a 
rotary evaporator under reduced pressure. The resulting crude oil 
crystallized at standing room temperature that gave the desired 
product 6 as yellowish powder, which was submitted to 
purification by recrystallization in absolute ethanol (1-3 ml). 
 
N-(4-Methylphenylcarbamothioyl)-1H-indole-2-carboxamide (6a) 
Compound 6a was prepared in 9% yield (173 mg) from 
p-toluidine 4a (628 mg, 598 µl, 6.2 mmol) according to the 
standard procedure. Mp = 200-202°C. 
1
H NMR (DMSO-d6) δ: 
2.32 (s, 3H), 7.09 (dd, 1H, J = 7.4, 0.9 Hz, Ar), 7.22 (d, 2H, J = 
7.7 Hz, Ar), 7.25-7.35 (m, 1H, Ar), 7.49 (d, 1H, J = 8.4 Hz, Ar), 
7.55 (d, 2H, J = 7.7 Hz, Ar), 7.68 (d, 1H, J = 7.8 Hz, Ar), 7.78 (s, 
1H, Ar), 11.48 (br s, 1H, NH), 12.07 (br s, 1H, NH), 12.58 (br s, 
1H, NH). 
13
C NMR (DMSO-d6) δ: 20.57 (CH3), 108.50, 112.58, 
120.36, 122.43, 124.28, 125.21, 126.75, 128.40, 129.06, 135.46, 
135.61, 137.78, 161.42 (C=O), 178.82 (C=S). HRMS, m/z: 
332.0835 found (calculated for C17H15N3ONaS [M+Na]
+
 requires 
332.0839). 
 
N-(Phenylcarbamothioyl)-1H-indole-2-carboxamide (6b) 
Compound 6b was prepared in 9% yield (165 mg) from 
aniline 4b (578 mg, 567 µl, 6.2 mmol) according to the standard 
procedure. Mp = 201-203°C. 
1
H NMR (DMSO-d6) δ: 7.05-7.18 
(m, 1H, Ar), 7.24-7.38 (m, 3H, Ar), 7.38-7.52 (m, 3H, Ar), 7.69 
(d, 2H, J = 7.8 Hz, Ar), 7.81 (s, 1H), 11.50 (br s, 1H, NH), 12.00 
(br s, 1H, NH), 12.63 (br s, 1H, NH). 
13
C NMR (DMSO-d6) δ: 
108.52, 112.58, 120.38, 122.46, 124.39, 125.25, 126.28, 126.75, 
127.51, 128.65, 130.16, 137.81, 138.01, 141.25, 161.43 (C=O), 
178.93 (C=S). HRMS, m/z: 318.0676 found (calculated for 
C16H13N3ONaS [M+Na]
+
 requires 318.0671). 
 
N-[(4-Fluorophenyl)carbamothioyl]-1H-indole -2- carboxamide 
(6c) 
Compound 6c was prepared in 18% yield (350 mg) from 
4-fluoroaniline 4c (690 mg, 588 µl, 6.2 mmol) according to the 
standard procedure. Mp = 199-201°C. 
1
H NMR (DMSO-d6) δ: 
7.05-7.13 (m, 1H, Ar), 7.16-7.34 (m, 4H, Ar), 7.49 (d, 1H, J = 8.7 
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Hz, Ar), 7.63-7.72 (m, 2H, Ar), 7.80 (s, 1H, Ar), 11.53 (s, 1H, 
NH), 11.99 (s, 1H, NH), 12.50 (s, 1H, NH). 
13
C NMR (DMSO-d6) 
δ: 108.52, 109.69, 112.58, 114.94, 120.38, 122.46, 125.25, 126.75, 
126.95, 127.06, 131.29, 132.12, 132.24, 137.81, 161.35 (C=O), 
179.52 (C=S). HRMS, m/z: 336.0590 found (calculated for 
C16H12N3O
19
FNaS [M+Na]
+
 requires 336.0577). 
 
N-[(3-Fluorophenyl)carbamothioyl]- 1H-indole-2-carboxamide 
(6d) 
Compound 6d was prepared in 75% yield (1.46 g) from 
3-fluoroaniline 4d (690 mg, 595 µl, 6.2 mmol) according to the 
standard procedure. Mp = 202-203°C. 
1
H NMR (DMSO-d6) δ: 
7.15 (dd, 1H, J = 7.4, 1.1 Hz, Ar), 7.22 (d, 1H, J = 7.7 Hz, Ar), 
7.25-7.30 (m, 1H, Ar), 7.33-7.49 (m, 3H, Ar), 7.55 (m, 1H, Ar), 
7.65 (d, 1H, J = 7.8 Hz, Ar), 7.70 (s, 1H, Ar), 11.48 (br s, 1H, 
NH), 12.00 (br s, 1H, NH), 12.50 (br s, 1H, NH). 
13
C NMR 
(DMSO-d6) δ: 108.62, 109.21, 112.18, 114.75, 120.47, 122.42, 
125.45, 126.72, 126.98, 127.00, 131.20, 132.05, 132.21, 137.74, 
161.35 (C=O), 179.42 (C=S). HRMS, m/z: 336.0584                    
found (calculated for C16H12N3O
19
FNaS [M+Na]
+
 requires 
336.0576). 
 
N-(Phenylmethylcarbamothioyl)-1H-indole-2-carboxamide (6e) 
Compound 6e was prepared in 80% yield (1.53 g) from 
benzylamine 4e (665 mg, 679 µl, 6.2 mmol) according to the 
standard procedure. Mp = 196-198°C. 
1
H NMR (DMSO-d6) δ: 
4.63 (s, 2H, CH2Ar), 7.12-7.22 (m, 1H, Ar), 7.29-7.38 (m, 3H, Ar), 
7.42-7.52 (m, 3H, Ar), 7.73 (d, 2H, J = 7.8 Hz, Ar), 7.80 (s, 1H, 
Ar), 11.58 (br s, 1H, NH), 11.94 (br s, 1H, NH), 12.60 (br s, 1H, 
NH). 
13
C NMR (DMSO-d6) δ: 55.32 (CH2), 108.52, 112.58, 
120.28, 122.66, 124.49, 125.24, 126.09, 126.71, 127.62, 128.64, 
131.01, 137.42, 138.11, 141.21, 161.12 (C=O), 178.02 (C=S). 
HRMS, m/z: 332.0941 found (calculated for C17H15N3ONaS 
[M+Na]
+
 requires 332.0936). 
 
N-(Morpholine-4-carbothioyl)-1H-indole-2-carboxamide (6f) 
Compound 6f was prepared in 78% yield (1.40 g) from 
morpholine 5a (541 mg, 546 µl, 6.2 mmol) according to the 
standard procedure. Mp = 180-182°C. 
1
H NMR (DMSO-d6) ฀: 
3.75 (s, 4H, CH2), 3.72 (s, 4H, CH2), 7.32 (d, 1H, J = 7.7 Hz, Ar), 
7.35-7.43 (m, 2H, Ar), 7.68 (d, 1H, J = 7.8 Hz, Ar), 7.80 (s, 1H, 
Ar), 11.50 (br s, 1H, NH), 12.52 (br s, 1H, NH). HRMS, m/z: 
312.3430 found (calculated for C14H15N3O2NaS [M+Na]
+
 requires 
312.3426). 
 
N-[(4-Methylpiperazine)-4-carbothioyl]-1H-indole-2-carboxamide 
(6g) 
Compound 6g was prepared in 75% yield (1.41 g) from 
4-methylpiperazine 5b (628 mg, 695 µl, 6.2 mmol) according to 
the standard procedure. Mp = 190-192°C. 
1
H NMR (DMSO-d6) δ: 
2.72 (s, 3H, Me), 3.75 (t, 4H, CH2), 3.98 (t, 4H, CH2), 7.30 (d, 1H, 
J = 7.7 Hz, Ar), 7.45-7.53 (m, 2H, Ar), 7.60 (d, 1H, J = 7.8 Hz, 
Ar), 7.75 (s, 1H, Ar), 11.42 (br s, 1H, NH), 12.42 (br s, 1H, NH). 
HRMS, m/z: 325.3846 found (calculated for C15H18N4ONaS 
[M+Na]
+
 requires 325.3844). 
Standard procedure for the synthesis of methylsulfanyl derivatives 
7(a-g). 
To a solution of compound 6 (1.81 mmol) in acetone p.a. 
(5 ml) mixed in a 50 ml round-bottomed flask provided with a 
magnetic stirrer and a condenser, was added successively methyl 
iodide MeI (770 mg, 335 µl, 5.43 mmol, 3 equiv) and anhydrous 
potassium carbonate K2CO3 (250 mg, 1.81 mmol). This             
reaction mixture was heated at 56°C in oil bath during                        
60 min. under vigorous magnetic stirring. After cooling                     
down to room temperature, 35 ml of deionized water was            
poured in the reaction mixture, then the resulting suspension was 
stored in a refrigerator (4°C) during 12 hr. The crystallized 
compound 7 was collected by filtration on a Buchner funnel 
(porosity N°4) and was dried under high vacuum (10
-2
 Torr)               
at 25°C for 1 hr. The product 7 was further used without 
purification. 
 
N-[(4-Methylphenylamino)methylsulfanyl -methylene]-1H-indole-
2-carboxamide (7a) 
Compound 7a was prepared in 66% yield (386 mg) from 
N-(4-methylphenylcarbamothioyl)-1H-indole-2-carboxamide 6a 
(560 mg, 1.81 mmol) according to the standard procedure. Mp = 
152-154°C. Yellowish Powder. 
1
H NMR (DMSO-d6) δ: 2.32 (s, 
3H, MeAr), 2.52 (s, 3H, SMe), 6.97-7.06 (m, 1H, Ar), 7.12 (s, 1H, 
Ar), 7.17-7.26 (m, 3H, Ar), 7.37 (d, 2H, J = 8.0 Hz, Ar), 7.45 (d, 
1H, J = 8.3 Hz, Ar), 7.63 (d, 1H, J = 7.8 Hz, Ar), 11.17 (br s, 1H, 
NH), 11.51 (br s, 1H, NH). 
13
C NMR (DMSO-d6) δ: 14.27 (MeAr), 
20.55 (SMe), 106.99, 112.46, 119.73, 121.87, 123.93, 124.68, 
129.43, 127.14, 134.92, 135.17, 135.89, 137.35, 160.02 (C=O). 
HRMS, m/z: 346.0988 found (calculated for C18H17N3ONaS 
[M+Na]
+
 requires 346.0984). 
 
N-[(Phenylamino)methylsulfanyl- methylene]- 1H-indole-2-
carboxamide (7b) 
Compound 7b was prepared in 52% yield (291 mg) from 
N-(phenylcarbamothioyl)-1H-indole-2-carboxamide 6b (534 mg, 
1.81 mmol) according to the standard procedure. Mp = 150-152°C. 
Yellowish Powder. 
1
H NMR (DMSO-d6) δ: 2.52 (s, 3H, SMe), 
6.98-7.14 (m, 2H, Ar), 7.18-7.30 (m, 3H, Ar), 7.37-7.46 (m, 3H, 
Ar), 7.52 (d, 2H, J = 8.0 Hz, Ar), 11.03 (br s, 1H, NH), 11.54 (br s, 
1H, NH). 
13
C NMR (DMSO-d6) δ: 22.63 (SMe), 100.23, 106.99, 
112.46, 119.81, 121.78, 123.91, 124.68, 127.18, 129.43, 134.90, 
135.21, 135.96, 137.35, 160.02 (C=O). HRMS, m/z: 332.0833 
found (calculated for C17H15N3ONaS [M+Na]
+
  requires 
332.0828). 
 
N-[(4-Fluorophenylamino)methylsulfanyl-methylene]-1H-indole-
2-carboxamide (7c) 
Compound 7c was prepared in 69% yield (409 mg) from 
N-[(4-fluorophenyl)carbamothioyl]-1H-indole-2-carboxamide 6c 
(567 mg, 1.81 mmol) according to the standard procedure. Mp = 
148-150°C. Yellowish Powder. 
1
H NMR (DMSO-d6) δ: 2.52 (s, 
3H, SMe), 7.41-7.50 (m, 2H, Ar), 7.54 (d, 2H, J = 6.2 Hz, Ar), 
7.62 (d, 2H, J = 7.7 Hz, Ar), 7.77-7.84 (m, 2H, Ar), 7.98 (d, 1H, J 
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= 7.6 Hz, Ar), 10.90 (br s, 1H, NH), 11.54 (br s, 1H, NH). 
13
C 
NMR (DMSO-d6) δ: 32.77 (SMe), 106.26, 115.49, 115.79, 121.91, 
123.99, 131.79, 132.89, 133.01, 134.81, 135.05, 137.36, 160,08 
(C=O). HRMS, m/z: 350.0736 found (calculated for 
C17H14N3O
19
FNaS [M+Na]
+
 requires 350.0733). 
 
N-[(3-Fluorophenylamino) methylsulfanyl-methylene]-1H-indole-
2-carboxamide (7d) 
Compound 7d was prepared in 62% yield (367 mg)           
from N-[(3-fluorophenyl)carbamothioyl]-1H-indole-2-
carboxamide 6d (567 mg, 1.81 mmol) according to the                
standard procedure. Mp = 149-151°C. Yellowish Powder.                  
1
H NMR (DMSO-d6) δ: 2.53 (s, 3H, SMe), 7.02 (s, 1H, Ar),   7.10-
7.37 (m, 6H, Ar), 7.45 (d, 1H, J = 8.3 Hz, Ar), 7.63 (d, 1H, J = 7.8 
Hz, Ar), 11.03 (br s, 1H, NH), 11.55 (br s, 1H, NH). 
13
C NMR 
(DMSO-d6) δ: 22.61 (SMe), 100.30, 106.99, 112.36, 119.84, 
121.68, 123.86, 124.10, 127.11, 129.43, 134.90, 135.18, 135.95, 
137.45, 160.05 (C=O). HRMS, m/z: 350.0738 found (calculated 
for C17H14N3O
19
FNaS [M+Na]
+
 requires 350.0733). 
 
N-[(Phenylmethylamino)methylsulfanyl-methylene]-1H-indole-2-
carboxamide (7e) 
Compound 7e was prepared in 65% yield (380 mg)           
from N-(phenylmethylcarbamothioyl)-1H-indole-2-carboxamide 
6e (560 mg, 1.81 mmol) according to the standard                 
procedure. Mp = 152-154°C. Yellowish Powder. 
1
H NMR 
(DMSO-d6) δ: 2.52 (s, 3H, SMe), 4.60 (s, 2H, CH2Ar), 7.00-7.08 
(m, 2H, Ar), 7.16-7.25 (m, 3H, Ar), 7.35-7.42 (m, 3H, Ar), 7.50 
(d, 2H, J = 8.0 Hz, Ar), 11.05 (br s, 1H, NH), 11.62 (br s, 1H, 
NH). 
13
C NMR (DMSO-d6) δ: 24.63 (SMe), 52.22 (CH2Ar), 
100.34 , 106.99, 112.32, 119.87, 121.68, 123.85, 124.10, 127.11, 
129.43, 134.90, 135.14, 135.95, 137.45, 160.12 (C=O). HRMS, 
m/z: 346.0990 found (calculated for C18H17N3ONaS [M+Na]
+
 
requires 346.0984). 
 
Methyl N-(1H-indol-2-carbonyl)morpholine-4 -carboximidothioate 
(7f) 
Compound 7f was prepared in 59% yield (324 mg) from 
N-(morpholine-4-carbothioyl)-1H-indole-2-carboxamide 6f (522 
mg, 1.81 mmol) according to the standard procedure. Mp = 158-
160°C. Yellowish Powder. 
1
H NMR (DMSO-d6) δ: 2.33 (s, 3H, 
SMe), 3.70 (s, 8H, CH2), 6.94 (s, 1H, Ar), 7.01 (dd, 1H, J = 11.0, 
3.9 Hz, Ar), 7.12-7.19 (m, 1H, Ar), 7.41 (d, 1H, J = 8.2 Hz, Ar), 
7.58 (d, 1H, J = 7.9 Hz, Ar), 11.45 (br s, 1H, NH). HRMS, m/z: 
326.0941 found (calculated for C15H17N3O2NaS [M+Na]
+
 requires 
326.0939). 
 
Methyl N-(1H-indol-2-carbonyl)- 4-methylpiperazine-1-
carboximidothioate (7g) 
Compound 7g was prepared in 64% yield (367                    
mg) from N-[(4-methylpiperazine)-4-carbothioyl]-1H-indole-2-
carboxamide 6g (547 mg, 1.81 mmol) according to the              
standard procedure. Mp = 162-164°C. Yellowish Powder. 
1
H 
NMR (DMSO-d6) δ: 1.69 (s, 3H, MeN), 3.28 (s, 3H, SMe), 3.61-
3.71 (m, 4H, Ar), 4.23-4.34 (m, 4H, Ar), 6.97 (s, 1H, Ar), 7.19-
7.43 (m, 2H, Ar), 7.45-7.57 (m, 1H, Ar), 7.75 (d, 1H, J = 8.0 Hz, 
Ar), 10.16 (br s, 1H, NH). HRMS, m/z: 339.1260                         
found (calculated for C16H20N4ONaS [M+Na]
+
 requires 339.1256). 
 
Standard procedure for the synthesis of 1-amino-imidazo[1,5-
a]indol-3-one derivatives 8(a-g). 
In a 50 ml round-bottomed flask provided with a 
magnetic stirrer and condenser was added successively compound 
7 (3 mmol), 5 ml of anhydrous dimethylformamide Me2NCHO 
and lithium hydride LiH [powder, 30 mesh, 95%] (50 mg, 6.3 
mmol, 2.1 equiv). The reaction mixture was stirred vigorously at 
room temperature under a stream of argon during 6 hr. After 
addition of cold deionized water (35 ml), the resulting reaction 
mixture was stored in a refrigerator (4°C) during 12 hr. The 
insoluble compound 8 was collected by filtration on a Buchner 
funnel (porosity N°4) and washed with deionized water (3x10 ml). 
The crude product 8 was purified by recrystallization in absolute 
ethanol and dried under high vacuum (10
-2
 Torr) at 25°C for 2 hrs 
that gave the desired product 8 as yellowish powder. 
 
1-(4-Methylphenylamino)imidazo[1,5-a]indol-3-one (8a) 
Compound 8a was prepared in 32% yield (264 mg) from 
N-[(4-methylphenylamino)methylsulfanyl-methylene]-1H -indole-
2-carboxamide 7a (970 mg, 3 mmol) according to the standard 
procedure. Mp = 152-154°C. 
1
H NMR (DMSO-d6) δ: 2.30 (s, 3H, 
MeAr), 6.98 (d, 2H, J = 8.2 Hz, Ar), 7.17 (d, 2H, J = 8.1 Hz, Ar), 
7.19 (s, 1H, =CH, Ar), 7.29 (dd, 1H, J = 7.4, 1.6 Hz, Ar), 7.49 (dd, 
1H, J = 7.4, 1.1 Hz, 1H), 7.80 (d, 1H, J = 8.0 Hz, Ar), 7.99 (d, 1H, 
J = 8.2 Hz, Ar), 11.22 (br s, 1H, NH). 
13
C NMR (DMSO-d6) δ: 
20.48 (CH3), 103.75, 113.33, 122.04, 122.94, 123.90, 126.93, 
129.57, 129.64, 131.66, 132.18, 132.76, 138.87, 143.23, 160.36 
(C-3, C=O). HRMS, m/z: 298.0959 found (calculated for 
C17H13N3ONa [M+Na]
+
 requires 298.0950). Anal. Calcd. for C, 
74.17; H, 4.76; N, 15.26. Found: C: 74.11; H, 4.73; N, 15.24. 
 
1-(Phenylamino)imidazo[1,5-a]indol-3-one (8b) 
Compound 8b was prepared in 34% yield (267 mg) from 
N-[(phenylamino)methylsulfany l-methylene]- 1H-indole-2-
carboxamide 7b (928 mg, 3 mmol) according to the standard 
procedure. Mp = 212-214°C. 
1
H NMR (DMSO-d6) δ: 7.07-7.17 
(m, 3H, Ar), 7.21 (s, 1H, =CH, Ar), 7.30 (dd, 1H, J = 7.6, 1.4 Hz, 
Ar), 7.34-7.41 (m, 2H, Ar), 7.50 (dd, 1H, J = 7.3 Hz, Ar), 7.81 (d, 
1H, J = 8.0 Hz, Ar), 7.99 (d, 1H, J = 8.1 Hz, Ar), 11.26 (br s, 1H, 
NH). 
13
C NMR (DMSO-d6) δ: 103.88, 113.32, 122.16, 122.99, 
123.83, 123.94, 126.99, 129.08, 129.71, 131.69, 132.22, 145.87, 
160.56 (C-3, C=O). HRMS, m/z: 284.0979 found (calculated for 
C16H12N3ONa [M+Na]
+
 requires 284.0902). Anal. Calcd. for C, 
73.55; H, 4.24; N, 16.08. Found: C: 73.69; H, 4.26; N, 16.11. 
1-(4-Fluorophenylamino)imidazo[1,5-a]indol-3-one (8c) 
Compound 8c was prepared in 27% yield (226 mg) from 
N-[(4-fluorophenylamino)methylsulfanyl -methylene]-1H-indole-
2-carboxamide 7c (982 mg, 3 mmol) according to the standard 
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procedure. Mp = 211-213°C. 
1
H NMR (DMSO-d6) δ: 7.06-7.23 
(m, 5H, Ar), 7.30 (dd, 1H, J = 7.5, 1.2 Hz, Ar), 7.49 (dd, 1H, J = 
7.6, 1.8 Hz, Ar), 7.80 (d, 1H, J = 8.0 Hz, Ar), 7.97 (d, 1H, J = 8.2 
Hz, Ar),  11.28 (br s, 1H, NH).   
13
C NMR (DMSO-d6)  δ: 104.05,  
113.32, 115.51, 115.81, 123.02, 123.64, 123.75, 123.94, 127.02, 
129.65, 131.69, 132.20, 139.58, 142.38, 157.42, 160.33 (C-3, 
C=O). HRMS, m/z: 302.0703 found (calculated for 
C16H10N3O
19
FNa [M+Na]
+
 requires 302.0700). Anal. Calcd. for C, 
68.81; H, 3.61; N, 15.05. Found: C: 68.89; H, 3.64; N, 15.09. 
 
1-(3-Fluorophenylamino)imidazo[1,5-a]indol-3-one (8d) 
Compound 8d was prepared in 52% yield (436 mg) from 
N-[(3-fluorophenylamino)methylsulfanyl-methylene]-1H-indole-2-
carboxamide 7d (982 mg, 3 mmol) according to the standard 
procedure. Mp = 220-222°C. 
1
H NMR (DMSO-d6) δ: 6.88-7.00 
(m, 3H, Ar), 7.23 (s, 1H, =CH, Ar), 7.26-7.44 (m, 2H, Ar), 7.50 
(dd, 1H, J = 7.3, 1.7 Hz, Ar), 7.81 (d, 1H, J = 8.0 Hz, Ar), 7.96 (d, 
1H, J = 8.2 Hz, Ar), 11.35 (br s, 1H, NH). 
13
C NMR (DMSO-d6) δ: 
104.32, 109.19, 109.49, 110.30, 110.58, 113.30, 123.08, 123.99, 
127.09, 129.69, 130.46, 131.71, 132.23, 139.95, 148.04, 160.37 
(C-3, C=O). HRMS, m/z: 302.0704 found (calculated for 
C16H10N3O
19
FNa [M+Na]
+
 requires 302.0700). Anal. Calcd. for C, 
68.81; H, 3.61; N, 15.05. Found: C: 68.86; H, 3.62; N, 15.07. 
 
1-(Phenylmethylamino)imidazo[1,5-a]indol-3-one (8e) 
Compound 8e was prepared in 22% yield (181 mg) from 
N-[(phenylmethylamino)methylsulfanyl-methylene]-1H -indole-2-
carboxamide 7e (970 mg, 3 mmol) according to the standard 
procedure. Mp = 222-224°C. 
1
H NMR (DMSO-d6) δ: 4.66 (s, 2H, 
CH2Ar), 7.13 (s, 1H, =CH, Ar), 7.19-7.31 (m, 2H, Ar), 7.32-7.53 
(m, 5H, Ar), 7.76 (d, 1H, J = 7.7 Hz, Ar), 7.93 (d, 1H, J = 7.1 Hz, 
Ar), 11.60 (br s, 1H, NH). 
13
C NMR (DMSO-d6) δ: 51.48 (CH2), 
103.02, 113.13, 122.64, 123.74, 126.57, 126.70, 127.31, 128.30, 
129.66, 131.54, 131.96, 139.85, 140.05, 160.33 (C-3, C=O). 
HRMS, m/z: 298.0959 found (calculated for C17H13N3ONa 
[M+Na]
+
 requires 298.0950). Anal. Calcd. for C, 74.17; H, 4.76; 
N, 15.26. Found: C: 74.21; H, 4.77; N, 15.27. 
 
Biochemistry 
Protein kinase assay buffers 
Buffer  A: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-
HCl pH 7.5, 50 µg heparin/ml. 
Buffer B: 60 mM β-glycerophosphate, 15 mM p-nitrophenyl-
phosphate, 25 mM Mops (pH 7.2), 5 mM EGTA, 15 mM MgCl2, 1 
mM DTT, 1 mM sodium vanadate, 1 mM phenylphosphate. 
 
Kinase preparations and assays 
Kinase activities for each enzyme were assayed in buffer 
A or B, with their corresponding substrates, in the presence                
of 15 µM ATP in a final volume of 30 µL. After 30 min incubation 
at 30°C, the reaction was stopped by harvesting, using a         
FilterMate harvester (Packard), onto P81 phosphocellulose            
papers (GE Healthcare) which were washed in 1%                
phosphoric acid. Scintillation fluid was added and the radioactivity 
measured in a Packard counter. Blank values were subtracted and 
activities calculated as pmoles of phosphate incorporated             
during the 30 min incubation. The activities were expressed in % 
of the maximal activity, i.e. in the absence of inhibitors. Controls 
were performed with appropriate dilutions of DMSO. 
CDK5/p25 (human, recombinant) was prepared as 
previously described (Leclerc et al., 2001). Its kinase activity was 
assayed in buffer B, with 1 mg histone H1/ml, in the presence of 
15 µM [γ-33P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume 
of 30 µl. After 30 min incubation at 30°C, 25 µl aliquots of 
supernatant were spotted onto 2.5 x 3 cm pieces of Whatman P81 
phosphocellulose paper, and, 20 s later, the filters were washed 
five times (for at least 5 min each time) in a solution of 10 ml 
phosphoric acid/liter of water. The wet filters were               
counted in the presence of 1 ml ACS (Amersham) scintillation 
fluid. 
DYRK1A (rat, recombinant, expressed in Escherichia coli 
as a GST fusion protein, provided by Dr. W. Becker) was purified 
by affinity chromatography on glutathione–agarose and assayed as 
described for CDK5/p25 using myelin basic protein (1 mg/ml) as a 
substrate. 
Casein kinase 1 (CK1δ/ε) (porcine brain, native) was 
assayed with 0.67 µg of CKS peptide (RRKHAAIGpSAYSITA), a 
CK1 specific substrate obtained from Millegen (Labege, France) 
(Reinhardt et al., 2007). 
GSK-3 (porcine brain, native) was assayed, as 
described for CDK5/p25 but in Buffer A and using a GSK-3 
specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) 
(pS stands for phosphorylated serine) (Primot et al., 2000). GS-1 
was synthesized by Millegen (Labege, France).  
CLK1 (mouse, recombinant, expressed in Escherichia 
coli as GST fusion proteins) was assayed in buffer A (+ 0.15 mg 
BSA /ml) with RS peptide (GRSRSRSRSRSR) (1µg/assay). 
 
RESULTS AND DISCUSSION 
For the preparation of the cyclized derivative of 
leucettine L41, the planned retrosynthesis of 1-aminoimidazo[1,5-
a]indol-3-ones (Figure 2) involved firstly, a ring closure by 
intramolecular sulphur/nitrogen displacement; secondly, activation 
of the carbon sulphur double bond by classical S-alkylation with 
an halogenoalcane; thirdly, thiourea synthesis by addition of 
primary or secondary amine on isothiocyanate function and 
fourthly, nucleophilic addition of thiocyanate anion on the indole-
2-carbonyl halide In order to synthesize the desired new 1-
aminoimidazo[1,5-a]indol-3-ones 8 (Scheme 1), commercial 
indole-2-carboxylic acid 1 was treated successively by 
phosphorous trichloride (Katritzky et al., 2004) under reflux at 
85°C during 2 hrs followed by addition of potassium 
isothiocyanate in acetone at room temperature for a supplementary 
reaction time of 1 hr (Abu-El-Halawa et al., 2008). Initial attempts 
to isolate the indole-2-carbonyl isothiocyanate 3 for complete 
caracterization by 
1
H, 
13
C NMR and HRMS analyses failed. This 
can be explained by the instability of intermediate 3 in the reaction 
medium during its preparation (Kutschy et al., 2000).  
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To obtain the desired product N,N'-disubstituted 
thioureas 6 from indole-2-carboxylic acid 1 in a reasonable yield, 
we decided to avoid isolation and purification of the indole-2-
carbonyl chloride 2 and indole-2-carbonyl isothiocyanate 3 
intermediates due to their instability under the hydrolytic work-up 
conditions. With the aim of introducing diversity on the N-1 
position of the desired 1-aminoimidazo[1,5-a]indol-3-ones 8, we 
examined the reactivity of indole-2-carbonyl isothiocyanate 3 with 
five primary amines 4(a-c) (i.e. p-toluidine 4a, aniline 4b, 4-
fluoroaniline 4c, 3-fluoroaniline 4d and benzylamine 4e) and two 
polar secondary cyclic amines 5(a,b) (i.e. morpholine 5a and N-
methylpiperazine 5b). The reaction of the intermediate 3                 
with the amines 4 and 5 afforded the corresponding thioureas 6(a-
g) as yellowish solids, which were purified by recrystallization 
from EtOH. As shown in Table 1, the N,N'-disubstituted          
thioureas    6 were   synthesized   in   low   to good yields (9-80%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to prepare the desired 1-aminoimidazo[1,5-a]indol-3-ones 
8 by cyclization, via intramolecular sulphur/nitrogen displacement, 
it was necessary to activate the C=S bond of the N,N'-disubstituted 
thioureas 6 with a halogenoalcane. S-alkylation of these N,N'-
disubstituted thioureas 6 was realized with 3 equivalents of methyl 
iodide in refluxed acetone in the presence of powdered potassium 
carbonate. Compounds 7(a-g) were obtained in 52-69% yields. To 
investigate the scope and limitation of the cyclization depicted in 
Scheme 1, we screened the reactivity of various bases in 
appropriate solvent (Et3N, pyridine, piperidine in acetonitrile, tert-
BuOK in tert-BuOH, AcONa in AcOH, NaH in THF or 1,4-
dioxane). No cyclization took place and starting compounds were 
recovered, thus indicating, that the choice of the base and the 
solvent was essential for successful ring closure. In fact, the 
lithium hydride (2 equivalents) in dry dimethylformamide 
mediated cyclization of compounds 7. This cyclization proceeded 
 
Fig. 2: Retrosynthetic strategy towards new 1-aminoimidazo[1,5-a]indol-3-ones 
 
 
Scheme. 1: Reagents and reaction conditions: (i) PCl3 2 equiv, C6H6, 2 hrs, 85°C. (ii) KSCN 1 equiv, acetone, 1 hr, 25°C. (iii) 4 or 5 1 equiv, 1 hr, 25°C. (iv) 
MeI 3 equiv, K2CO3 1 equiv, acetone, 1 hr, reflux. (v) LiH 2 equiv, dry DMF, 6 hrs, 25°C. 
 
 
Fig. 3: Possible transient intermediate during reaction of methylsulfanyl isothioureas 7(f,g) in the presence of lithium hydride. 
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via intramolecular nucleophilic attack of the deprotonated indole 
nitrogen on the highly electrophilic carbon atom of the enamide 
bond C=N bearing the methylsulfanyl leaving group of the 
isothioureas 7. The 1-aminoimidazo[1,5-a]indol-3-ones                      
8 were easily isolated after quenching the crude reaction           
mixture with cold deionized water and the insoluble             
compound 8 was collected by filtration and was recrystallized 
from EtOH.  
As can be seen in Table 1, cyclization worked well with 
methylsulfanyl isothioureas 7(a-e) derived from primary amines 
4(a-e) while, on the contrary, cyclization failed with compounds 
7(f,g) derived from cyclic secondary amines 5(a,b) even in the 
presence of ten-fold excess of lithium hydride. This might be 
explained by the decrease of the electrophilic character on the 
carbon atom of the enamide C=N bond or by the bulky effect of 
morpholine-1-yl or N-methylpiperazine-1-yl moiety in the possible 
transient intermediate (Figure 3) which decreases the leaving 
character of the methylsulfanyl group. 
 
Table. 1: Results for the preparation of compounds 6(a-g), 7(a-g) and 1-amino 
imidazo[1,5-a]indol-3-one derivatives 8(a-g). 
Compound R n X Yield
a
 (%) 
6a 4-Me 0 - 9 
6b H 0 - 9 
6c 4-F 0 - 18 
6d 3-F 0 - 75 
6e H 1 - 80 
6f - - O 78 
6g - - NMe 75 
7a 4-Me 0 - 66 
7b H 0 - 52 
7c 4-F 0 - 69 
7d 3-F 0 - 62 
7e H 1 - 65 
7f - - O 59 
7g - - NMe 64 
8a 4-Me 0 - 32 
8b H 0 - 34 
8c 4-F 0 - 27 
8d 3-F 0 - 52 
8e H 1 - 22 
8f - - O - 
8g - - NMe - 
a
 Isolated yields. 
 
As can be seen in Table 1, compounds 8(a-e) were 
isolated in yields ranging from 27 to 52%. The structure 
identification of these five new 1-aminoimidazo[1,5-a]indol-3-
ones 8(a-e) were based on the 
1
H and 
13
C assignments and was 
performed extensive 1D and 2D NMR spectroscopy. Examination 
of the 
1
H NMR spectra in DMSO-d6 showed that the CH= proton 
of the indolyl moiety of 8(a-e) appears at low field (7.13 ppm < 
δindol < 7.21 ppm).  
It is interesting to note that there is only one               
signal for the NH proton in the 
1
H NMR spectra of 8(a-e) (11.22 
ppm < δNH < 11.60 ppm), which strongly indicates the cyclized 
structure of these compounds. For the methylsulfanyl precursors 
7(a-e), we observed two separated signals for the NH protons.           
As example, in the 
1
H NMR spectrum of 7a in DMSO-d6,                
the first NH broad singulet appears at 11.17 ppm and the            
second shifted to 11.51 ppm. The five new 1-aminoimidazo             
[1,5-a]indol-3-ones 8(a-e) were evaluated against five              
different and representative kinases. Harmine (a natural β- 
carboline alkaloid known to be a potent inhibitor of DYRK1A 
(Tahtouh et al., 2012 and Göckler et al., 2009)) was also used as 
positive control and its IC50 values were compared with those 
obtained for the compounds 8. Results given in Table 2 
demonstrated that 1-aminoimidazo[1,5-a]indol-3-ones 8 are 
inactive against DYRK1A, CK1, CDK5/p25, GSK3  and 
CLK1, except for compound 8b for which an IC50 value of 9 µM 
was determined. 
 
Table 2: Effects of the 1-amino imidazo[1,5-a]indol-3-one derivatives 8(a-
e).on the catalytic activity of four purified protein kinases
a
. 
Compound DYRK1A CK1 CDK5/p25 GSK3 CLK1 
8a >10 >10 >10 >10 >10 
8b 9 >10 >10 >10 >10 
8c >10 >10 >10 >10 >10 
8d - - - - - 
8e >10 >10 >10 >10 >10 
Leucettine L41 0.040 - - >10 0.090 
Harmine 0.029 1.5 >10 >10 0.072 
(R)-Roscovitine 11 2.3 0.2 130 NT 
a
Compounds were tested at various concentrations on each kinase as described 
in Experimental Section. IC50 values, calculated from the dose-response curves, 
are reported in µM. -, inactive at the highest concentration tested (10 µM); >10, 
inhibitory but IC50 > 10 µM. 
 
CONCLUSION 
 
In summary, we worked out the synthesis in 5 steps of 
new 1-aminoimidazo[1,5-a]indol-3-ones 8(a-e) without 
substituents on the indole moiety. The key step of this sequence is 
the ring closure by intramolecular sulphur/nitrogen displacement 
in basic medium with S-methylsulfanyl thioureas 7 derivatives 
issued from primary amines.  
Among these cyclized compounds 8, only 8b           
presented modest micromolar inhibition activity on DYRK1A 
(IC50 9 mM). Now, we are interested in further explorations for 
introduction of molecular diversity with appropriate groups on the 
indole moiety of compounds 8, in order to increase the biological 
properties of these new 1-aminoimidazo[1,5-a]indol-3-ones           
with potential applications in Alzheimer's disease/Down 
syndrome. 
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